Additional analysis showed that reduction and long-term maintenance of normal serum urate levels also reduced risk of future gout flares Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to ULORIC ® (febuxostat) treatment. A subset of subjects from the CONFIRMS trial who received prior urate-lowering therapy for up to five years achieved sUA gout flares than patients who had not received prior long-term urate-lowering therapy. According to Michael Becker, M.D., professor emeritus of medicine, rheumatology section, The University of Chicago School of Medicine, gout associated with hyperuricemia is a chronic condition that requires long-term management.
Ardea Biosciences Announces Additional Positive Results From A Phase 2a Study Of RDEA594 At The 2009 ACR ARHP Annual Scientific Meeting
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. These results, as well as data from a preclinical drug-drug interaction study demonstrating RDEA594's potential to be used in combination with allopurinol and febuxostat ( Uloric ® , Takeda Pharmaceutical Company Limited; Adenuric® , Ipsen), are being presented today at the 2009 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania. In the first cohort of this small placebo- and active-controlled study of 21 gout patients with hyperuricemia (serum urate â 8 mg/dL), 11 patients were randomized to blinded RDEA594 200 mg once-daily (qd) for one week followed by RDEA594 400 mg qd for one week, 5 patients were randomized to blinded placebo for two weeks and 5 patients were randomized to open-label allopurinol 300 mg qd for two weeks.
PHILADELPHIA - New data show that low-dose colchicine (Colcrys TM ) rapidly controls acute gout flares. The results, which were presented at the 2009 Annual Scientific Meeting of the American College of Rheumatology, are drawn from a secondary analysis of the phase III Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial. Robert Terkeltaub, MD, with the Veterans Affairs Medical Center in San Diego, presented data in 184 gout patients who were randomized to high-dose colchicine (1.2 mg, then 0.6 mg hourly x 6 hours = 4.8 mg total), low-dose colchichine (1.2 mg, then 0.6 mg in 1 hour = 1.8 mg total, followed by 5 placebo doses hourly), or placebo (2 capsules, then 1 capsule hourly x 6 hours). Colchicine has been used for centuries for the treatment of gout flares but, until recently, it has not been studied extensively for safety and efficacy in controlled trials.
Ardea Biosciences Reports Positive Results For RDEA594, Its Lead Product Candidate For Gout, In Combination With Allopurinol Or Febuxostat
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive results from the second panel of a Phase 1 drug-drug interaction and pharmacodynamic study of RDEA594 in combination with febuxostat ( Uloric ® , Takeda Pharmaceutical Company Limited; Adenuric® , Ipsen and Menarini). "The impressive reduction in serum urate observed when RDEA594 and febuxostat or allopurinol are co-administered indicate that these oral agents with complementary mechanisms may be able to produce reductions in serum urate previously achieved only with intravenous therapy, " said Mark Genovese, MD, professor of medicine and Co-Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center and a member of Ardea's scientific advisory board.
Women with gout are at greater risk of a heart attack than men with the disease, indicates research published ahead of print in the Annals of the Rheumatic Diseases. Gout is known to boost the risk of a heart attack in men. But to date, little has been known about the impact of gout on women's cardiovascular health. Gout is common and caused by inflammation in the joints as a result of excess uric acid deposits. Uric acid is a by-product of purines, which are abundant in a Western diet. Obesity, weight gain, high alcohol intake, high blood pressure, poorly functioning kidneys and certain drugs can all precipitate its development. The authors base their findings on a population study of more than 9500 gout patients and 48, 000 people without the disease, aged 65 and older. All participants were drawn from the Canadian British Columbia Linked Health Database, which covers the entire province of British Columbia (population 4.